In a report released today, Mark Massaro from Canaccord Genuity maintained a Buy rating on Quest Diagnostics Inc (DGX), with a price target of $98. The company’s shares closed yesterday at $87.94, close to its 52-week low of $87.40.
“We stick with our BUY rating, and lower our PT from $105 to $98, based on 14.3x our 2020 adj. EPS estimate.”
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 15.5% and a 56.5% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.
Currently, the analyst consensus on Quest Diagnostics Inc is a Moderate Buy with an average price target of $109.25, representing a 24.2% upside. In a report released yesterday, Credit Suisse also maintained a Buy rating on the stock with a $121 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $116.49 and a one-year low of $87.40. Currently, Quest Diagnostics Inc has an average volume of 1.13M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers.